CLINICAL_TRIALS
trial_result
· 2025-10-02
Clinical Trial Update: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment [Phase 3]
Summary
A Phase 3 trial evaluating the antipsychotic ITI-007 for schizophrenia has completed and posted results after 6 weeks of treatment.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-10-02